| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
31,012 |
19,182 |
$503K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
3,391 |
2,535 |
$309K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
14,439 |
10,520 |
$219K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
36,032 |
21,057 |
$170K |
| Q0247 |
Injection, sotrovimab, 500 mg |
42 |
33 |
$35K |
| 91322 |
|
382 |
360 |
$14K |
| 90480 |
|
615 |
565 |
$11K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
759 |
675 |
$11K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
49 |
46 |
$7K |
| M0240 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses |
42 |
33 |
$5K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
113 |
94 |
$4K |
| 0003A |
|
933 |
647 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
174 |
169 |
$2K |
| M0201 |
Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home |
1,507 |
935 |
$1K |
| 0001A |
|
269 |
157 |
$1K |
| 90688 |
|
319 |
276 |
$791.00 |
| 90658 |
|
101 |
99 |
$723.62 |
| 0002A |
|
63 |
51 |
$572.27 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
21 |
21 |
$462.48 |
| 99072 |
|
16,042 |
10,432 |
$394.01 |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
458 |
268 |
$270.00 |
| 0013A |
|
49 |
39 |
$200.00 |
| 91320 |
|
37 |
37 |
$143.52 |
| 0011A |
|
26 |
18 |
$80.00 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
1,467 |
1,027 |
$0.04 |
| 90710 |
|
118 |
103 |
$0.00 |
| 91300 |
|
487 |
330 |
$0.00 |
| 91321 |
|
96 |
80 |
$0.00 |
| 90707 |
|
127 |
116 |
$0.00 |
| 90713 |
|
169 |
155 |
$0.00 |
| 90700 |
|
76 |
65 |
$0.00 |
| 90648 |
|
72 |
64 |
$0.00 |
| 90633 |
|
399 |
341 |
$0.00 |
| 90715 |
|
131 |
127 |
$0.00 |
| 90661 |
|
33 |
33 |
$0.00 |
| Q0245 |
Injection, bamlanivimab and etesevimab, 2100 mg |
27 |
25 |
$0.00 |
| 90716 |
|
265 |
240 |
$0.00 |
| 90744 |
|
117 |
111 |
$0.00 |
| 90651 |
|
61 |
61 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
85 |
59 |
$0.00 |
| 90677 |
|
198 |
169 |
$0.00 |
| 90619 |
|
18 |
18 |
$0.00 |
| Q0240 |
Injection, casirivimab and imdevimab, 600 mg |
16 |
14 |
$0.00 |
| 90656 |
|
18 |
17 |
$0.00 |